ADAPTIVE BIOTECHNOLOGIES CORPORATION Cost of Revenue
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Cost of Revenue of $20.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for the quarter ending 2026-06-30 was $20.16M, a 12.03% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for the quarter ending 2026-03-31 was $18.71M, a 10.18% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for the quarter ending 2025-12-31 was $18.22M, a 0.99% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for the quarter ending 2025-09-30 was $18.16M, a 8.94% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for fiscal 2025 was $71.36M, a 1.00% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for fiscal 2024 was $72.08M, a 4.60% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for fiscal 2023 was $75.55M, a 30.47% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION cost of goods and services sold for fiscal 2022 was $57.91M, a 17.46% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.16M 10-Q · filed 2026-08-04 | $38.87M 10-Q · filed 2026-08-04 | $57.10M derived: sum of 3 quarters · filed 2026-08-04 | $75.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $18.71M 10-Q · filed 2026-05-05 | $36.93M derived: sum of 2 quarters · filed 2026-05-05 | $55.09M derived: sum of 3 quarters · filed 2026-05-05 | $73.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $18.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.38M derived: sum of 2 quarters · filed 2026-02-26 | $54.38M derived: sum of 3 quarters · filed 2026-08-04 | $71.36M 10-K · filed 2026-02-26 |
| 2025-09-30 | $18.16M 10-Q · filed 2025-11-05 | $36.16M derived: sum of 2 quarters · filed 2026-08-04 | $53.13M 10-Q · filed 2025-11-05 | $71.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $18.00M 10-Q · filed 2026-08-04 | $34.98M 10-Q · filed 2026-08-04 | $53.02M derived: sum of 3 quarters · filed 2026-08-04 | $69.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $16.98M 10-Q · filed 2026-05-05 | $35.02M derived: sum of 2 quarters · filed 2026-05-05 | $51.69M derived: sum of 3 quarters · filed 2026-05-05 | $71.01M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $18.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.71M derived: sum of 2 quarters · filed 2026-02-26 | $54.03M derived: sum of 3 quarters · filed 2026-02-26 | $72.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.67M 10-Q · filed 2025-11-05 | $35.98M derived: sum of 2 quarters · filed 2025-11-05 | $54.03M 10-Q · filed 2025-11-05 | $73.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $19.32M 10-Q · filed 2025-08-05 | $37.37M 10-Q · filed 2025-08-05 | $56.98M derived: sum of 3 quarters · filed 2026-02-26 | $76.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $18.05M 10-Q · filed 2025-05-01 | $37.67M derived: sum of 2 quarters · filed 2026-02-26 | $57.01M derived: sum of 3 quarters · filed 2026-02-26 | $74.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $19.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.96M derived: sum of 2 quarters · filed 2026-02-26 | $56.87M derived: sum of 3 quarters · filed 2026-02-26 | $75.55M 10-K · filed 2026-02-26 |
| 2023-09-30 | $19.35M 10-Q · filed 2024-11-07 | $37.26M derived: sum of 2 quarters · filed 2024-11-07 | $55.94M 10-Q · filed 2024-11-07 | $72.53M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $17.91M 10-Q · filed 2024-08-01 | $36.59M 10-Q · filed 2024-08-01 | $53.18M derived: sum of 3 quarters · filed 2025-03-03 | $68.09M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $18.68M 10-Q · filed 2024-05-07 | $35.27M derived: sum of 2 quarters · filed 2025-03-03 | $50.18M derived: sum of 3 quarters · filed 2025-03-03 | $63.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $16.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $31.50M derived: sum of 2 quarters · filed 2025-03-03 | $44.72M derived: sum of 3 quarters · filed 2025-03-03 | $57.91M 10-K · filed 2025-03-03 |
| 2022-09-30 | $14.91M 10-Q · filed 2023-11-09 | $28.13M derived: sum of 2 quarters · filed 2023-11-09 | $41.32M 10-Q · filed 2023-11-09 | $55.68M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $13.22M 10-Q · filed 2023-08-02 | $26.41M 10-Q · filed 2023-08-02 | $40.77M derived: sum of 3 quarters · filed 2024-02-29 | $54.96M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $13.19M 10-Q · filed 2023-05-03 | $27.55M derived: sum of 2 quarters · filed 2024-02-29 | $41.74M derived: sum of 3 quarters · filed 2024-02-29 | $52.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $14.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $28.55M derived: sum of 2 quarters · filed 2024-02-29 | $39.31M derived: sum of 3 quarters · filed 2024-02-29 | $49.30M 10-K · filed 2024-02-29 |
| 2021-09-30 | $14.19M 10-Q · filed 2022-11-03 | $24.95M derived: sum of 2 quarters · filed 2022-11-03 | $34.95M 10-Q · filed 2022-11-03 | $41.17M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $10.77M 10-Q · filed 2022-08-03 | $20.76M 10-Q · filed 2022-08-03 | $26.98M derived: sum of 3 quarters · filed 2023-02-14 | $33.03M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $9.99M 10-Q · filed 2022-05-04 | $16.21M derived: sum of 2 quarters · filed 2023-02-14 | $22.27M derived: sum of 3 quarters · filed 2023-02-14 | $27.18M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $12.28M derived: sum of 2 quarters · filed 2023-02-14 | $17.19M derived: sum of 3 quarters · filed 2023-02-14 | $22.53M 10-K · filed 2023-02-14 |
| 2020-09-30 | $6.05M 10-Q · filed 2021-11-03 | $10.96M derived: sum of 2 quarters · filed 2021-11-03 | $16.31M 10-Q · filed 2021-11-03 | $22.26M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $4.91M 10-Q · filed 2021-08-04 | $10.26M 10-Q · filed 2021-08-04 | $16.21M derived: sum of 3 quarters · filed 2022-02-15 | $21.81M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $5.34M 10-Q · filed 2021-05-05 | $11.29M derived: sum of 2 quarters · filed 2022-02-15 | $16.89M derived: sum of 3 quarters · filed 2022-02-15 | $22.63M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $5.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $11.55M derived: sum of 2 quarters · filed 2022-02-15 | $17.29M derived: sum of 3 quarters · filed 2022-02-15 | $22.27M 10-K · filed 2022-02-15 |
| 2019-09-30 | $5.60M 10-Q · filed 2020-11-10 | $11.34M derived: sum of 2 quarters · filed 2020-11-10 | $16.32M 10-Q · filed 2020-11-10 | $21.60M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $5.73M 10-Q · filed 2020-08-10 | $10.72M 10-Q · filed 2020-08-10 | $16.00M derived: sum of 3 quarters · filed 2021-02-24 | $21.36M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $4.99M 10-Q · filed 2020-05-12 | $10.26M derived: sum of 2 quarters · filed 2021-02-24 | $15.62M derived: sum of 3 quarters · filed 2021-02-24 | $20.67M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $10.63M derived: sum of 2 quarters · filed 2021-02-24 | $15.68M derived: sum of 3 quarters · filed 2021-02-24 | $19.67M 10-K · filed 2021-02-24 |
| 2018-09-30 | $5.36M 10-Q · filed 2019-11-12 | $10.40M derived: sum of 2 quarters · filed 2019-11-12 | $14.39M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $5.04M 10-Q · filed 2019-08-13 | $9.03M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $15.68M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |